Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly
DGAP-News: Medios AG
/ Key word(s): Takeover/Expansion
Berlin, 21 January 2021 - Today, Medios successfully completed the takeover of the specialized pharmaceutical wholesaler Cranach Pharma GmbH, Hamburg. With the entry of the capital increase in kind in the commercial register, all closing conditions have now been fulfilled, meaning that the acquisition is completed. The German Federal Cartel Office had already granted clearance on 21 December 2020. As a result, Medios is now the largest provider of Specialty Pharma solutions in Germany.
Through the merger with Cranach Pharma GmbH, Medios' partner network has grown from around 330 to around 500 specialized pharmacies. For the 2021 financial year, Medios expects, including the acquired Cranach Pharma GmbH, a significant increase in group sales to more than €1 billion.
Matthias Gärtner, Chairman of the Executive Board and Chief Financial Officer of Medios AG: "We are pleased to add our long-standing partner, Cranach Pharma, to the Medios Group. The acquisition strengthens our position as a full-service provider of Specialty Pharma solutions and gives us the opportunity to leverage an even broader product offering, as well as synergies in purchasing, sales and logistics. Our goal is to grow both organically and inorganically. We are well prepared for further acquisitions."
The seller of Cranach Pharma GmbH is BMSH GmbH, which already holds a stake in Medios. The purchase price was paid in the form of 4,180,000 new Medios shares, which were created from authorized capital within a capital increase against contribution in kind. This is approximately 20.6% of the Medios share capital, after implementation of the capital increase. The purchase price for Cranach Pharma thus amounts to roughly €120.8 million based on a share price of approximately €28.90 per share. As a result, the share capital of Medios AG has increased from €16,084,991 to €20,264,991. Existing shareholdings of shareholders are reduced accordingly, so that reporting thresholds may also be undercut and voting rights notifications may become necessary. The new shares are subject to staggered lock-up periods of up to 24 months. As part of the acquisition, Medios will provide Cranach Pharma with funding of approximately €30 million to strengthen its working capital and finance further growth.
About Medios AG
Medios AG is Germany's first listed Specialty Pharma company and member of the SDAX selection index. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).
21.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 30 232 566 - 800|
|Fax:||+49 30 232 566 - 801|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||1159262|
|End of News||DGAP News Service|